Purvalanol B

Cat. No. 1581

Purvalanol B C20H25ClN6O3 [212844-54-7]

Price and Availability

For Purvalanol B pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Name: NG 95

Chemical Name: (2R)-2-[[6-[(3-Chloro-4-carboxyphenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-1-butanol

Biological Activity

Cyclin-dependent kinase inhibitor. IC50 values are 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively. Selective over a range of other protein kinases (IC50 > 10,000 nM). Shown to have antiproliferative properties, mediated by p42/p44 MAPK.

Licensing Information

Sold under license from the Regents of the University of California

Technical Data

M.Wt:
432.91
Formula:
C20H25ClN6O3
Solubility:
Soluble to 100 mM in 1eq. NaOH with gentle warming and to 100 mM in DMSO
Purity:
>99 %
Storage:
Store at +4°C
CAS No:
212844-54-7

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Product Datasheet / Safety Datasheet

Certificate of Analysis / Product Datasheet
Select another batch:

References are publications that support the products' biological activity.

Knockaert et al (2002) p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene 21 6413. PMID: 12226745.

Gray et al (1999) ATP-site directed inhibitors of cyclin-dependent kinases. Curr.Med.Chem. 6 859. PMID: 10495356.

Gray et al (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281 533. PMID: 9677190.

If you know of a relevant reference for Purvalanol B please let us know.

Citations are publications that use Tocris products. Selected citations for Purvalanol B include:

Schreiber et al (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9 1047. PMID: 20071362.

Wissing et al (2007) Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. J Pharmacol Exp Ther 6 537. PMID: 17192257.

Do you know of a great paper that uses Purvalanol B from Tocris? If so please let us know.

View Related Products by Target

View Related Products by Product Action

Keywords: Purvalanol B, supplier, Cyclin-dependent, protein, kinases, inhibitors, inhibits, Cdk, PurvalanolB, NG95, Tocris Bioscience, Cyclin-Dependent Protein Kinase Inhibitor products

Quick Order

Find multiple products by catalog number

divider line

Neurodegeneration Research Product Guide

Neurodegeneration Product Guide

Our Neurodegeneration guide highlights over 275 products for neurodegeneration research. Request copy or view PDF today.

divider line

Cancer Research Product Guide

Cancer Research Product Guide

Our Cancer Research Guide highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Kinase Inhibitor Toolbox

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

Kinases Product Listing

Kinases Product Listing

Our Kinase listing highlights over 400 products for kinase research. Request copy or view PDF today.

divider line

Cell Cycle & DNA Damage Repair

Cell Cycle & DNA Damage Repair Life Science Poster

Our Cell Cycle & DNA Damage Repair poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death. Request copy or view PDF today.

divider line

New Products in this Area

ML 315 hydrochloride

Inhibitor of Clk and DYRK kinases

Everolimus

mTOR inhibitor;immunosuppressant

PKI (5-24)

High affinity PKA inhibitor

TDZD 8

Selective non-ATP competitive inhibitor of GSK 3β

BI 605906

Selective IKKβ inhibitor

GSK 319347A

Potent and selective IKKε inhibitor

FRAX 597

Potent group I PAK inhibitor

MRT 68921 dihydrochloride

Potent ULK inhibitor; inhibits autophagy

AM 2394

Potent glucokinase activator; orally bioavailable

eCF 309

Potent mTOR inhibitor

PF 3758309 dihydrochloride

Potent PAK4 inhibitor; orally available

AZ Dyrk1B 33

Potent and selective Dyrk1B kinase inhibitor

PF 06409577

Potent and selective allosteric activator of AMPK

Perifosine

PKB/Akt inhibitor; also modulates Kv2.1 current

RAF 265

Raf kinase and VEGFR-2 inhibitor

CZC 25146

Potent LRRK2 inhibitor

Ro 3280

Potent and selective PLK1 inhibitor

RMM 46

MSK/RSK family kinase inhibitor

LTURM 34

Potent DNA-PK inhibitor

MLi-2

Potent and selective LRRK2 inhibitor

LTURM 36

PI 3-kinase δ inhibitor

PI 3065

Potent and selective PI 3-kinase p110δ inhibitor

Sign-up for new product e-alerts
divider line

Twitter Updates

Follow @Tocris on Twitter

Follow us on Twitter!

Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.